DE69806066D1 - Affinitätsmarkierer für menschliches serum albumin - Google Patents

Affinitätsmarkierer für menschliches serum albumin

Info

Publication number
DE69806066D1
DE69806066D1 DE69806066T DE69806066T DE69806066D1 DE 69806066 D1 DE69806066 D1 DE 69806066D1 DE 69806066 T DE69806066 T DE 69806066T DE 69806066 T DE69806066 T DE 69806066T DE 69806066 D1 DE69806066 D1 DE 69806066D1
Authority
DE
Germany
Prior art keywords
serum albumin
human serum
affinity marker
molecule
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69806066T
Other languages
English (en)
Other versions
DE69806066T2 (de
Inventor
Alexander Krantz
Wolin Huang
M Hanel
L Holmes
P Bridon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Application granted granted Critical
Publication of DE69806066D1 publication Critical patent/DE69806066D1/de
Publication of DE69806066T2 publication Critical patent/DE69806066T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69806066T 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin Expired - Lifetime DE69806066T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07
US7792798P 1998-03-13 1998-03-13
PCT/US1998/023705 WO1999024075A2 (en) 1997-11-07 1998-11-06 Affinity markers for human serum albumin

Publications (2)

Publication Number Publication Date
DE69806066D1 true DE69806066D1 (de) 2002-07-18
DE69806066T2 DE69806066T2 (de) 2003-02-06

Family

ID=26744806

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69806066T Expired - Lifetime DE69806066T2 (de) 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin
DE69839946T Expired - Fee Related DE69839946D1 (de) 1997-11-07 1998-11-06 Methoden zum Screening von Affinitätsmarker-Bibliotheken

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69839946T Expired - Fee Related DE69839946D1 (de) 1997-11-07 1998-11-06 Methoden zum Screening von Affinitätsmarker-Bibliotheken

Country Status (8)

Country Link
US (1) US7166695B2 (de)
EP (2) EP1056474B1 (de)
AT (2) ATE406577T1 (de)
AU (1) AU1519699A (de)
CA (2) CA2628053A1 (de)
DE (2) DE69806066T2 (de)
ES (1) ES2178854T3 (de)
WO (1) WO1999024075A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
WO2000069902A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
EP1355941A2 (de) 2001-02-02 2003-10-29 ConjuChem, Inc. Langwirkende derivate des wachstumshormon freisetzenden faktors
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
EP1592801B1 (de) 2003-01-17 2010-05-05 Advanced Proteome Therapeutics Inc. Verfahren zur Identifizierung aktivierter Polymer-Komplexe zur sekundären Stellen-spezifischen Modifikation von Protein Ziel-Gruppen.
PT1745078E (pt) 2004-04-23 2009-09-17 Conjuchem Biotechnologies Inc Método para a purificação de conjugados de albumina
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
CA2708762A1 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
CA3013829A1 (en) * 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity labels
KR20240046307A (ko) * 2017-04-28 2024-04-08 아지노모토 가부시키가이샤 가용성 단백질에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US4808705A (en) 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
GB8713240D0 (en) 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
DE3731297C1 (de) 1987-09-17 1989-05-18 Rexroth Mannesmann Gmbh Schaltventilanordnung
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
ATE135045T1 (de) 1988-07-23 1996-03-15 Delta Biotechnology Ltd Sekretorische leader-sequenzen
WO1990003799A1 (en) 1988-10-12 1990-04-19 Centocor, Inc. Radiotherapeutic immunoconjugates labeled with iodine-125
US5250662A (en) 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5182366A (en) 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
ATE176239T1 (de) 1990-11-21 1999-02-15 Iterex Pharma Lp Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
US5616311A (en) 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
ES2097925T3 (es) 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
JPH0692968A (ja) * 1992-09-16 1994-04-05 Nakarai Tesuku Kk ビオチン導入試薬
CA2144067A1 (en) 1992-09-24 1994-03-31 Ronald N. Zuckermann Synthesis of n-substituted oligomers
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5571681A (en) 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
US20030100007A1 (en) 1995-12-18 2003-05-29 Howard Benjamin Methods for identifying compounds that bind to a target
AU713616B2 (en) * 1996-01-12 1999-12-09 Conjuchem, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification

Also Published As

Publication number Publication date
ATE218892T1 (de) 2002-06-15
ATE406577T1 (de) 2008-09-15
DE69806066T2 (de) 2003-02-06
AU1519699A (en) 1999-05-31
EP1056474A2 (de) 2000-12-06
CA2628053A1 (en) 1999-05-20
US20050037974A1 (en) 2005-02-17
WO1999024075A2 (en) 1999-05-20
US7166695B2 (en) 2007-01-23
ES2178854T3 (es) 2003-01-01
EP1056474B1 (de) 2002-06-12
CA2305597A1 (en) 1999-05-20
DE69839946D1 (de) 2008-10-09
CA2305597C (en) 2008-07-29
WO1999024075A3 (en) 1999-09-02
EP2033661A1 (de) 2009-03-11

Similar Documents

Publication Publication Date Title
DE69806066D1 (de) Affinitätsmarkierer für menschliches serum albumin
DE69731476D1 (de) Kupplungen für medizinische kanülen
DE69525293D1 (de) Inhalationsgerät für medizinische Zwecke
DE50014571D1 (de) Träger-pharmaka-konjugate
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
DE69634171D1 (de) Mikroverkapselte laktobazillen für medizinische anwendungen
DE69605940T2 (de) Wärmeaktivierbare klebstoffzusammensetzung
DE69834596D1 (de) Etectrochirurghische, blutstillende klammervorrichtung
DE69800460D1 (de) Katheteranordnung zum intrakardialen Nähen
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
PT749433E (pt) COMPOSTOS ANELARES, HETEROCíCLICOS OU CARBOCíCLICOS, SUBSTITUIDOS COM (4,4-DIFLUOROBUT-3-ENILTIO), QUE POSSUEM ACTIVIDADE PESTICIDA
FR2716363B1 (fr) Instrument de thérapie endoscopique.
DE69022115D1 (de) Hämostatische, chirurgische Clips.
DE69731794D1 (de) Innenschutz für eine vaskuläre Anastomose
KR970703365A (ko) 그룹 B 연쇄상구균의 비-IgA Fc 결합 형태의 클로닝
DE69535295D1 (de) Informationsanbietersystem
TR199600753A1 (tr) Ikame edilmis benzoilguanidin'leri, bunlarin imal edilmesine mahsus usul, bunlarin ilac ya da diyagnoz maddesi olarak kullanilmalari ve ayrica bunlari ihtiva eden ilaclar.
DE29700307U1 (de) Zerstäuber für medizinische Zwecke
DE69513747D1 (de) Ventilanschluss für medizinische Injektionsstelle
DE29605790U1 (de) Spritze für medizinische Zwecke
FR2718448B3 (fr) Dérivés d'acides aminoboroniques, leur préparation et leur utilisation comme intermédiaires de synthèse.
DE69427858T2 (de) Schnelles diagnoseverfahren für ivermectin-resistenz
FR2759747B1 (fr) Clip d'agrafage
DE69302847T2 (de) Wasserdichtes, hitzeaktivierbares Band für das Buchbinden
DE29708126U1 (de) Zentralvenöser Katheterschnellverband

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,